Skip to main content

Table 5 Weight management, blood glucose and blood lipids: Non-caloric versus Sucrose

From: A systematic review on the effect of sweeteners on glycemic response and clinically relevant outcomes

Non-caloric

sweetener

Population

Timepoint (week)

No of participants

MD (95% CI)

BMI, kg/m2

Aspartame

General

4

133

-0.3 (-1.1,0.5)

Mixturea

Overweight

10

41

-0.9 (-1.5,-0.4)

Weight, kg

Cyclamate

DM1

4

10

0.8 (-3.3,4.9)

Mixture

Overweight

10

41

-2.6 (-3.7,-1.5)

Day Energy Intake, kcal

Aspartame

General

4

133

-283 (-414,-153)

Mixture

Overweight

10

41

-491 (-806,-177)

HbA1C, %

Cyclamate

DM1

4

10

-0.02 (-0.4,0.3)

HOMA Index

Mixture

Overweight

10

41

-0.20 (-0.58,0.18)

Total Cholesterol, mmol/L

Cyclamate

DM1

4

10

-0.34 (-0.87,0.19)

HDL Cholesterol, mmol/L

Cyclamate

DM1

4

10

-0.05 (-0.32,0.22)

Triglycerides, mmol/L

Cyclamate

DM1

4

10

-0.02 (-0.16,0.12)

Mixture

Overweight

10

41

-0.26 (-0.85,0.34)

  1. aAspartame, acesulfame, cyclamate, saccharin
  2. DM1, Type 1 Diabetes Mellitus; DM2, Type 2 Diabetes Mellitus; BMI, Body mass index; HbA1C, Glycated haemoglobin; HOMA, Homeostatic Model Assessment; MD, Mean difference; CI, Confidence interval
  3. Statistically significant results are bolded.